Title:Altered Expression of TRIM Proteins - Inimical Outcome and
Inimitable Oncogenic Function in Breast Cancer with Diverse
Carcinogenic Hallmarks
Volume: 23
Issue: 1
关键词:
TRIM蛋白，泛素系统，乳腺癌，缺氧，临床意义，肿瘤发生，化疗耐药性。
摘要: Deregulation of ubiquitin-mediated degradation of oncogene products or
tumor suppressors appears to be implicated in the genesis of carcinomas, according to
new clinical findings. Conferring to recent research, some members of the tripartite motif
(TRIM) proteins (a subfamily of the RING type E3 ubiquitin ligases) act as significant
carcinogenesis regulators. Intracellular signaling, development, apoptosis, protein
quality control, innate immunity, autophagy, and carcinogenesis are all regulated by
TRIM family proteins, the majority of which have E3 ubiquitin ligase activity. The
expression of TRIMs in tumors is likely to be related to the formation and/or progression
of the disease, and TRIM expression could be used to predict cancer prognosis. Breast
cancer is the most common malignancy in women and also the leading cause of death.
TRIM family proteins have unique, vital activities, and their dysregulation, such as TRIM
21, promotes breast cancer, according to growing evidence. Many TRIM proteins have
been identified as important cancer biomarkers, with decreased or elevated levels of
expression. TRIM29 functions as a hypoxia-induced tumor suppressor gene, revealing a
new molecular mechanism for ATM-dependent breast cancer suppression. In breast
cancer cells, the TRIM28-TWIST1-EMT axis exists, and TRIM28 enhances breast
cancer metastasis by stabilizing TWIST1, and thereby increasing epithelial-tomesenchymal
transition. Interestingly, many TRIM proteins are involved in the control of
p53, and many TRIM proteins are likewise regulated by p53, according to current
research. Furthermore, TRIMs linked to specific tumors may aid in the creation of
innovative TRIM-targeted cancer treatments. This review focuses on TRIM proteins that
are involved in tumor development, progression, and are of clinical significance in breast
cancer.
